Digitalis refers to a group of cardiac glycosides derived primarily from plants of the genus Digitalis, particularly purple foxglove (Digitalis purpurea) and woolly foxglove (Digitalis lanata).
The medicinal use of foxglove dates back several centuries. One of the earliest documented references appeared around 1250 in a Welsh medical text associated with the Physicians of Myddfai. During the 16th and 17th centuries, foxglove appeared in European herbal medicine and was recommended for various conditions, including epilepsy, tuberculosis, and dropsy (an old medical term for generalized edema). However, its use was inconsistent because the therapeutic effects varied considerably with the preparation and dosage. The plant was also recognized as potentially poisonous, and inappropriate administration sometimes caused serious adverse effects. By the mid-18th century, digitalis had fallen into relative disuse because of concerns about its toxicity [1; 2].
The turning point in the history of digitalis came with the work of William Withering. After approximately ten years of clinical experience and systematic observations, Withering published his landmark book in 1785, An Account of the Foxglove, and Some of Its Medical Uses.
He described the beneficial effects of foxglove in patients with dropsy, particularly those whose edema was associated with heart disease. Importantly, he also documented adverse reactions and recognized that the difference between an effective dose and a toxic dose could be very small.
Withering’s work was groundbreaking because he systematically documented clinical responses, recognized the importance of dosage control, and described characteristic toxic effects, including nausea, vomiting, visual disturbances, and an abnormally slow pulse. Although he did not understand the underlying molecular mechanisms, his work established digitalis as an important therapeutic agent and laid the foundation for clinical pharmacology [1; 3; 4].
During the 19th century, researchers increasingly recognized that the therapeutic effects of foxglove were attributable to specific active chemical constituents rather than the plant as a whole.
French pharmacists Homolle and Quevenne developed concentrated digitalis preparations in the 1840s. In the 1860s, Claude-Adolphe Nativelle isolated a more purified crystalline digitalis preparation. In 1875, German pharmacologist Oswald Schmiedeberg reported the isolation of digitoxin, an important active cardiac glycoside found in purple foxglove.
These developments represented a major transition from crude herbal extracts to chemically characterized pharmaceutical preparations. Nevertheless, variations in drug potency and absorption remained important clinical problems until more reliable purification and standardization methods became available [1; 4].
A particularly important milestone occurred in 1930, when British chemist Sydney Smith isolated digoxin from the leaves of Digitalis lanata (woolly foxglove). Smith published his discovery in the Journal of the Chemical Society under the title “Digoxin, a New Digitalis Glucoside” [5].
Digoxin subsequently became one of the most widely used cardiac glycosides because of its established pharmacological activity and clinical usefulness. By the middle of the 20th century, it had become a widely prescribed medication for congestive heart failure and atrial fibrillation [1; 6].
The major mechanism of action of digoxin involves inhibition of the sodium-potassium ATPase (Na⁺/K⁺-ATPase) pump in cardiac muscle cells.
This produces two major effects:
These mechanisms explain its two major cardiovascular actions: positive inotropy and slowing of atrioventricular nodal conduction [7; 6].
For much of the 20th century, digitalis was a cornerstone of treatment for congestive heart failure. However, its role has changed considerably with the development of modern cardiovascular medications.
The Digitalis Investigation Group (DIG) trial, published in 1997, was an important milestone in evaluating digoxin using randomized clinical trial methods. It demonstrated that digoxin did not reduce overall mortality in patients with heart failure and reduced ejection fraction who were in sinus rhythm, but it reduced hospitalization due to worsening heart failure [8; Full NEJM article].
Today, digoxin retains a selective clinical role in patients with symptomatic heart failure despite guideline-directed medical therapy and in selected patients requiring ventricular rate control for atrial fibrillation.
However, digoxin has a narrow therapeutic index. Toxicity may cause gastrointestinal symptoms, visual disturbances, bradycardia, atrioventricular block, and potentially life-threatening arrhythmias. Renal function, age, electrolyte disturbances, and drug interactions can substantially affect its safety. Careful dose selection and clinical monitoring remain essential [7; 9].
Digitalis occupies a unique place in medical history. Its development demonstrates how traditional herbal medicine can lead to the discovery of an effective modern drug through systematic clinical observation, chemical isolation, and experimental investigation. The history of digitalis illustrates a fundamental principle of pharmacology: a drug can have substantial therapeutic benefits while also producing serious toxicity, making appropriate patient selection, dosage, and monitoring essential.
1. Wray S, Eisner DA, Allen DG. Two hundred years of the foxglove. Medical History. 1985; Supplement 5:132–150. PubMed.
2. Withering W. An Account of the Foxglove. 1785. Wellcome Collection.
3. Bessen HA. Therapeutic and toxic effects of digitalis: William Withering, 1785. Journal of Emergency Medicine. 1986;4:243–248. DOI.
4. Krikler DM. The foxglove, “The old woman from Shropshire” and William Withering. Journal of the American College of Cardiology. 1985;5:3A–9A. PubMed.
5. Smith S. Digoxin, a new digitalis glucoside. Journal of the Chemical Society. 1930:508–510. DOI.
6. Whayne TF Jr. Clinical Use of Digitalis: A State of the Art Review. American Journal of Cardiovascular Drugs. 2018;18:427–440. DOI.
7. Digoxin. StatPearls. NCBI Bookshelf.
8. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine. 1997;336:525–533. DOI.
9. Digoxin prescribing information. FDA.
Note: Edited from ChatGPT
This website uses cookies.